News
PGT-A fails a cost test in Israel, as Ontario weighs saying no to public funding
· IVF Automation News
Summary
A peer-reviewed model from Tel Aviv University, published on 2 November 2026, finds that routine PGT-A would cost Israel’s public IVF programme more than standard morphology-based embryo selection without adding live births, in every age group and embryo-count scenario it tested. It lands as Ontario Health’s draft advice against publicly funding PGT-A, issued in June, moves toward a final decision.
PGT-A, the chromosome screening of embryos before transfer, has become one of the most widely sold IVF add-ons. Two public payers have now looked hard at what they would get for the money, and both have come back cautious.
What did the Israeli study find?
Einat Zivi and colleagues built a Markov decision model from the public payer’s point of view. It followed women from the moment their usable blastocysts are counted (one to eight) through repeated single embryo transfers, until a live birth or until the embryos run out. Costs came from Israel’s 2025 Ministry of Health tariffs and clinic prices for the test. Clinical probabilities came from the US SART database.
The result was clear within the model’s terms: skipping PGT-A was cheaper and gave an equal or higher chance of a live birth, so it “dominated” PGT-A. The authors conclude that PGT-A “cannot be recommended for public funding within the Israeli public IVF program.”
The gap narrows with age. For women aged 38 to 40 with four blastocysts, PGT-A became cost-neutral only if the test fell to about 1,075 shekels per embryo. For women aged 41 to 42, the break-even was about 2,449 shekels, which the authors say is close to current prices at several Israeli clinics. Even then, PGT-A stayed slightly less effective in the model.
Why would screening embryos mean fewer births?
The authors stress that the lower birth rate is a product of their assumptions, not proof that PGT-A harms embryos. The model allowed only euploid embryos to be transferred and excluded mosaic results. Any viable embryo wrongly labelled abnormal leaves the pool for good. Measured per transfer, PGT-A looks strong. Measured per batch of blastocysts, which is what a patient actually has, the advantage fades.
The study has real limits. It ignored stimulation and egg collection costs, used US outcome data for an Israeli population, and could not model women over 42, although Israel funds IVF up to 45. It also assumed biopsy does no harm and that every result is conclusive. The authors declared no external funding and no competing interests.
What is Ontario deciding?
Ontario Health’s June 2026 draft recommends against publicly funding PGT-A for people having IVF. Its review of six randomised trials found PGT-A may make little to no difference to live birth after the first planned transfer, and the evidence on cumulative live birth is very uncertain. It may reduce pregnancy loss among people who become pregnant, but with low-certainty evidence and no gain in time to live birth. Funding PGT-A would cost an estimated C$139 million over five years. Public comment closed on 9 July, and IVF.net reported on 4 November that a final recommendation is still to come. The draft is about public funding, not whether clinics may offer the test.
The UK regulator, the HFEA, already rates PGT-A red for increasing the chance of a baby for most patients.
What does this mean for IVF labs and clinic owners?
- Report outcomes per patient, not just per transfer. Both reviews turn on that difference. A lab KPI dashboard that tracks cumulative live birth per retrieval gives a fairer picture.
- Know your own numbers. Euploidy rates by age, “no result” rates and your mosaic transfer policy all change the value of the test for your patients.
- Counsel on what PGT-A can and cannot do. Ontario flagged false positives, false negatives and inconsistent mosaic handling as concerns.
- Watch who pays. A Northwestern abstract at ASRM 2026, reported by Medscape on 2 November, linked capped insurance cover to higher PGT-A use (odds ratio 2.10). It is preliminary, but it suggests coverage rules shape demand.
What is the India angle?
Section 25 of India’s ART (Regulation) Act, 2021 says pre-implantation genetic testing “shall be used to screen the human embryo for known, pre-existing, heritable or genetic diseases only.” How that wording applies to routine aneuploidy screening is a question for clinics’ legal advisers and the National Board. Most Indian IVF is paid out of pocket, so the payer debate abroad will reach patients here mainly through counselling and price. Our ART Act compliance checklist covers the wider rules, and our AI embryo assessment guide looks at another selection tool still waiting on outcome evidence.
What is the commercial outlook?
Neither document bans PGT-A, and both leave room for selective use, especially in older patients. But public payers are moving toward prognosis-based use rather than testing every embryo. For PGT-A providers, the pressure points are price per embryo and cumulative live-birth data. Ontario’s final recommendation is the next date to watch.
This article reports research and health policy. It is not medical or legal advice.
Sources
- Einat Zivi, Moshe Leshno, Ariel Hammerman, Tomer Ziv-Baran, “Preimplantation genetic testing for aneuploidy (PGT-A) vs. morphology-based blastocyst selection for transfer: cost-effectiveness analysis within Israel’s publicly funded IVF system”, Israel Journal of Health Policy Research, published 2 Nov 2026 (peer-reviewed, open access). https://doi.org/10.1186/s13584-026-00790-z
- Ontario Health, “Preimplantation Genetic Testing for Aneuploidy, Monogenic Disorders, and Structural Rearrangements: Draft Recommendations”, June 2026 (draft; public comment 18 June to 9 July 2026). https://ontariohealth.ca/content/dam/ontariohealth/documents/filter-list/hta/recommendation-preimplantation-genetic-testing-draft-2606-en.pdf
- IVF.net Newsdesk, “PGT-A may not improve live birth rates on highly uncertain evidence, Ontario Health finds, with draft advice against funding in Ontario”, 4 Nov 2026 (news report). https://ivf.net/ivf/pgt-a-may-not-improve-live-birth-rates-on-highly-uncertain-evidence-ontario-health-finds-with-draft-o14167.html
- Human Fertilisation and Embryology Authority, “Pre-implantation genetic testing for aneuploidy (PGT-A)”, treatment add-on rating (regulator guidance, accessed 5 Nov 2026). https://www.hfea.gov.uk/treatments/treatment-add-ons/pre-implantation-genetic-testing-for-aneuploidy-pgt-a/
- Karen Blum, “Insurance Limits Increase Use of Embryo Genetic Testing for IVF”, Medscape, 2 Nov 2026 (report of an ASRM 2026 abstract; preliminary). https://www.medscape.com/viewarticle/insurance-limits-increase-use-embryo-genetic-testing-ivf-2026a10015kd
- Government of India, The Assisted Reproductive Technology (Regulation) Act, 2021, section 25 (statute, via PRS Legislative Research). https://prsindia.org/files/bills_acts/acts_parliament/2021/The%20Assisted%20Reproductive%20Technology%20(Regulation)%20Act,%202021.pdf
Tags: PGT-A cost-effectiveness, PGT-A live birth rate, preimplantation genetic testing aneuploidy, PGT-A public funding, Ontario Health PGT-A, Israel IVF PGT-A study, ART Act section 25 PGT India, IVF add-ons